CN215426375U - Covered stent - Google Patents
Covered stent Download PDFInfo
- Publication number
- CN215426375U CN215426375U CN202022958478.9U CN202022958478U CN215426375U CN 215426375 U CN215426375 U CN 215426375U CN 202022958478 U CN202022958478 U CN 202022958478U CN 215426375 U CN215426375 U CN 215426375U
- Authority
- CN
- China
- Prior art keywords
- stent
- release
- slow
- medicine
- layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 claims abstract description 77
- 229940079593 drug Drugs 0.000 claims abstract description 40
- 230000008929 regeneration Effects 0.000 claims abstract description 10
- 238000011069 regeneration method Methods 0.000 claims abstract description 10
- 230000002137 anti-vascular effect Effects 0.000 claims abstract description 8
- 239000010410 layer Substances 0.000 claims description 53
- 239000012528 membrane Substances 0.000 claims description 14
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 9
- 229960002897 heparin Drugs 0.000 claims description 9
- 229920000669 heparin Polymers 0.000 claims description 9
- 229930012538 Paclitaxel Natural products 0.000 claims description 4
- 229960001592 paclitaxel Drugs 0.000 claims description 4
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 4
- 229960002930 sirolimus Drugs 0.000 claims description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 4
- 229920000295 expanded polytetrafluoroethylene Polymers 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 229910001000 nickel titanium Inorganic materials 0.000 claims description 3
- 239000007888 film coating Substances 0.000 claims 1
- 238000009501 film coating Methods 0.000 claims 1
- 230000035931 haemagglutination Effects 0.000 claims 1
- 230000002792 vascular Effects 0.000 abstract description 18
- 208000037803 restenosis Diseases 0.000 abstract description 15
- 210000004204 blood vessel Anatomy 0.000 abstract description 14
- 208000014674 injury Diseases 0.000 abstract description 13
- 230000006378 damage Effects 0.000 abstract description 11
- 206010020718 hyperplasia Diseases 0.000 abstract description 10
- 230000002093 peripheral effect Effects 0.000 abstract description 7
- 210000001367 artery Anatomy 0.000 abstract description 4
- 230000008733 trauma Effects 0.000 abstract description 4
- 210000002489 tectorial membrane Anatomy 0.000 abstract 1
- 239000010408 film Substances 0.000 description 39
- 208000027418 Wounds and injury Diseases 0.000 description 10
- 239000011247 coating layer Substances 0.000 description 6
- 239000008280 blood Substances 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000015271 coagulation Effects 0.000 description 3
- 238000005345 coagulation Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 206010003162 Arterial injury Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
Images
Abstract
The utility model discloses a covered stent, which relates to the technical field of drug-coated stents and comprises a stent; be equipped with first nanometer slow-release medicine thin layer on the support, first nanometer slow-release medicine thin layer can slowly release anti vascular tissue intima regeneration medicine, and anti vascular tissue intima regeneration medicine can resist the hyperplasia of vascular tissue intima, avoids the blood vessel to be because of the vascular intimal hyperplasia restenosis that the damage arouses, consequently, the tectorial membrane support that this application provided can reduce the vascular intimal hyperplasia restenosis probability of peripheral artery damage that leads to because of the trauma.
Description
Technical Field
The utility model relates to the technical field of drug-coated stents, in particular to a covered stent.
Background
Peripheral arterial injury caused by traffic injury and modern war injury is often treated by using a covered stent for emergency treatment and hemostasis, but the restenosis rate of a blood vessel after the intervention of a common covered stent for hemostasis is high; although the heparin covered stent achieves good clinical curative effect in peripheral vascular injury and reduces the vascular restenosis rate, the current clinical application is imported heparin covered stent, the covered stent only uses heparin coating, the heparin coating does not have the function of resisting vascular intimal regeneration, and the blood vessel with peripheral arterial injury caused by traffic injury and modern war injury is easy to cause vascular restenosis due to vascular intimal hyperplasia in the middle and long term, therefore, when the covered stent only with the heparin coating is used for treating the vascular diseases, the capacity of treating vascular restenosis due to vascular intimal hyperplasia in the middle and long term is weak, and the visceral vascular restenosis rate after interventional operation is as high as 30%, so a novel covered stent is urgently needed.
SUMMERY OF THE UTILITY MODEL
The utility model aims to provide a covered stent, which solves the problems in the prior art and reduces the probability of vascular intimal hyperplasia restenosis of peripheral artery injury caused by trauma.
In order to achieve the purpose, the utility model provides the following scheme:
the utility model provides a covered stent, comprising: a support; the stent is provided with a first nano slow-release drug film layer which can slowly release anti-vascular tissue intimal regeneration drugs.
Preferably, the stent is also provided with a second nano slow-release drug film layer which can slowly release the anti-hemagglutination drug.
Preferably, the first nano slow-release drug film layer and the second nano slow-release drug film layer are both multilayer.
Preferably, the bracket is annular, the first nano slow-release medicine film layer covers the inner wall of the bracket, and the second nano slow-release medicine film layer covers one side surface of the first nano slow-release medicine film layer, which is far away from the bracket.
Preferably, the membrane further comprises a semi-permeable membrane layer, the semi-permeable membrane layer is provided with holes, and the semi-permeable membrane layer covers one side of the second nanometer slow-release drug film layer, which is far away from the first nanometer slow-release drug film layer.
Preferably, the outer wall of the bracket is covered with an outer coating layer.
Preferably, the drug in the first nano slow-release drug film is rapamycin or paclitaxel, and the drug in the second nano slow-release drug film is heparin.
Preferably, the outer covering film layer is made of expanded polytetrafluoroethylene film.
Preferably, the stent is a nickel titanium alloy stent.
Compared with the prior art, the utility model has the following technical effects:
the utility model provides a covered stent, wherein a first nano slow-release medicine film layer is arranged on the stent and can slowly release anti-vascular tissue intima regeneration medicines which can resist hyperplasia of vascular tissue intima and avoid vascular intimal hyperplasia restenosis caused by injury of blood vessels, so that the covered stent provided by the application can reduce the probability of vascular intimal hyperplasia restenosis of peripheral artery injury caused by trauma.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings needed in the embodiments will be briefly described below, and it is obvious that the drawings in the following description are only some embodiments of the present invention, and it is obvious for those skilled in the art to obtain other drawings without creative efforts.
FIG. 1 is a schematic structural view of a stent graft provided by the present invention;
FIG. 2 is a schematic view of the structure of a semipermeable membrane in a stent graft provided by the present invention;
in the figure: 1-stent, 2-outer coating layer, 3-second nano slow-release drug film layer, 4-first nano slow-release drug film layer, 5-semi-permeable film layer and 6-hole.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The utility model aims to provide a covered stent, which aims to solve the problems in the prior art and reduce the restenosis rate of middle and long term blood vessels.
In order to make the aforementioned objects, features and advantages of the present invention comprehensible, embodiments accompanied with figures are described in further detail below.
The utility model provides a covered stent, as shown in figures 1-2, comprising: a bracket 1; the stent 1 is provided with a first nano slow-release medicine film layer 4, and the first nano slow-release medicine film layer 4 can slowly release anti-vascular tissue intima regeneration medicines; the anti-vascular tissue intimal regeneration medicine can resist hyperplasia of vascular tissue intima, and can avoid vascular intimal proliferative restenosis caused by injury of blood vessels, so that the covered stent provided by the application can reduce the probability of vascular intimal proliferative restenosis of peripheral artery injury caused by trauma.
Further, in order to avoid restenosis caused by blood coagulation in the blood vessel, the second nano slow-release drug film layer 3 is further arranged on the stent 1, the second nano slow-release drug film layer 3 can slowly release the anti-blood coagulation drug, and the anti-blood coagulation drug can prevent blood coagulation.
Furthermore, the first nano slow-release medicine film layer 4 and the second nano slow-release medicine film layer 3 are both multilayer, so that the treatment effect is enhanced.
Further, the stent 1 is annular, the first nano slow-release drug film layer 4 covers the inner wall of the stent 1, the drugs for resisting intimal regeneration of vascular tissues released by the first nano slow-release drug film layer 4 can penetrate through the stent 1 to act on the inner wall of blood vessels, the second nano slow-release drug film layer 3 covers one side surface, far away from the stent 1, of the first nano slow-release drug film layer 4, and the anti-blood coagulation drugs released by the second nano slow-release drug film layer 3 directly enter blood.
Further, the drug delivery device further comprises a semi-permeable membrane layer 5, a hole 6 is formed in the semi-permeable membrane layer 5, the semi-permeable membrane layer 5 covers one side, far away from the first nanometer slow-release drug membrane layer 4, of the second nanometer slow-release drug membrane layer 3, and the drug can enter a blood vessel through the hole 6 in the semi-permeable membrane layer 5.
Further, in order to rapidly stop bleeding, an outer coating layer 2 is coated on the outer wall of the stent 1, the outer coating layer 2 is used for preventing blood from flowing out from the wound of the blood vessel, and the anti-vascular tissue intima regeneration medicine slowly released by the first nano slow-release medicine film 4 can penetrate through the outer coating layer 2 to act on the inner wall of the blood vessel.
Further, the drug in the first nano slow-release drug film 4 is rapamycin or paclitaxel, and the drug in the second nano slow-release drug film 3 is heparin.
Further, the outer coating layer 2 is made of an expanded polytetrafluoroethylene film.
Further, the stent 1 is a nickel-titanium alloy stent which has low density and does not react with body fluid.
The preparation method of the nano sustained-release medicine film comprises the following steps:
a) dissolving the medicine, cholesterol and phospholipid in organic solvent.
b) Evaporating the solvent to make the medicine and the film-forming material such as phospholipid form a uniform lipoid film on the inner wall of the flask.
c) Adding flushing liquid to wash the membrane to obtain liposome suspension.
d) The liposome with the particle size of 50 +/-12 nm is prepared by combining the thin film evaporation method and the freeze drying method.
e) The prepared liposome is uniformly covered on the inner side of the bracket layer by layer, and finally, a semipermeable membrane with micropores is covered on the inner side of the bracket to obtain the multilayer nano slow-release medicine film.
When in use, the stent is implanted into a blood vessel, so that the medicine in the inner multilayer nano slow-release medicine film seeps out to prevent the near-far stage restenosis of the blood vessel, the blood vessel cavity layer of the medicine film is a heparin nano-medicine coating film, and the near-stent layer is a rapamycin and paclitaxel nano-medicine film layer.
The principle and the implementation mode of the utility model are explained by applying a specific example, and the description of the embodiment is only used for helping to understand the method and the core idea of the utility model; meanwhile, for a person skilled in the art, according to the idea of the present invention, the specific embodiments and the application range may be changed. In view of the above, the present disclosure should not be construed as limiting the utility model.
Claims (7)
1. A stent graft, comprising: the method comprises the following steps: a support; be equipped with first nanometer slow-release medicine thin layer on the support, first nanometer slow-release medicine thin layer can slowly release anti vascular tissue inner membrance regeneration medicine, still be provided with second nanometer slow-release medicine thin layer on the support, second nanometer slow-release medicine thin layer can slowly release anti hemagglutination medicine, the support is the annular, first nanometer slow-release medicine thin layer cover in on the support inner wall, second nanometer slow-release medicine thin layer cover in first nanometer slow-release medicine thin layer is kept away from on a side of support.
2. The stent-graft of claim 1, wherein: the first nano slow-release medicine film layer and the second nano slow-release medicine film layer are both multilayer.
3. The stent-graft of claim 1, wherein: the membrane layer is covered on one side of the second nanometer slow-release medicine film layer, which is far away from the first nanometer slow-release medicine film layer.
4. The stent-graft of claim 1, wherein: the outer wall of the bracket is covered with an outer film coating layer.
5. The stent-graft of claim 1, wherein: the drug in the first nano slow-release drug film is rapamycin or paclitaxel, and the drug in the second nano slow-release drug film is heparin.
6. The stent-graft of claim 4, wherein: the outer covering film layer is made of an expanded polytetrafluoroethylene film.
7. The stent graft of any one of claims 1-6, wherein: the stent is a nickel-titanium alloy stent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202022958478.9U CN215426375U (en) | 2020-12-09 | 2020-12-09 | Covered stent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202022958478.9U CN215426375U (en) | 2020-12-09 | 2020-12-09 | Covered stent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN215426375U true CN215426375U (en) | 2022-01-07 |
Family
ID=79680810
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202022958478.9U Expired - Fee Related CN215426375U (en) | 2020-12-09 | 2020-12-09 | Covered stent |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN215426375U (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115252215A (en) * | 2022-07-26 | 2022-11-01 | 上海百心安生物技术股份有限公司 | Novel covered stent capable of improving blood flow velocity and characterization method |
| CN115487410A (en) * | 2022-11-18 | 2022-12-20 | 山东瑞安泰医疗技术有限公司 | Preparation method of drug eluting stent for preventing hyperplasia and thrombus |
-
2020
- 2020-12-09 CN CN202022958478.9U patent/CN215426375U/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115252215A (en) * | 2022-07-26 | 2022-11-01 | 上海百心安生物技术股份有限公司 | Novel covered stent capable of improving blood flow velocity and characterization method |
| CN115487410A (en) * | 2022-11-18 | 2022-12-20 | 山东瑞安泰医疗技术有限公司 | Preparation method of drug eluting stent for preventing hyperplasia and thrombus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5980551A (en) | Composition and method for making a biodegradable drug delivery stent | |
| CN215426375U (en) | Covered stent | |
| JP3614652B2 (en) | Drug-containing porous metal prosthesis | |
| US20050037052A1 (en) | Stent coating with gradient porosity | |
| US20020055710A1 (en) | Medical device for delivering a therapeutic agent and method of preparation | |
| JPH11505135A (en) | Nitric oxide releasing nitroso compositions and devices for their use in preventing restenosis | |
| JPH10295824A (en) | Production of medicine-containing porous metallic artificial organ | |
| KR20080073328A (en) | Controlled drug release composition and drug releasing medical device | |
| JP2008540022A (en) | Implantable charged medical device | |
| KR20180110214A (en) | Implant comprising a non-woven fabric | |
| JP2010540199A (en) | Diarsenic trioxide drug-eluting stent | |
| CN105833358B (en) | Intracranial drug eluting stent system and preparation method thereof | |
| CN109602518B (en) | Fluid-gated artificial blood vessel | |
| EP0652017B2 (en) | Coating for biomaterial | |
| CN106175983B (en) | Overlay film frame and its manufacturing method | |
| CN107865868B (en) | New application of amlexanox | |
| Rosenthal et al. | Medium-term results of experimental stent implantation into the ductus arteriosus | |
| KR101082935B1 (en) | Method of manufacturing porous film for anti-adhesive-membrane and slow emission materials | |
| JP4851086B2 (en) | Coating composition for implantable medical device and method for coating the device | |
| Song et al. | Ultrasound controlled paclitaxel releasing system—A novel method for improving the availability of coronary artery drug coated balloon | |
| EP3003417B1 (en) | Compositions for blood vessel tissue repair | |
| JP4456322B2 (en) | Stent | |
| KR20220088945A (en) | Drug-eluting stent | |
| CN101513540A (en) | Drug-eluting coronary artery stent and method for preparing same | |
| CN106730049B (en) | Biocompatible internal stent material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220107 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |